Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence

García, J.R.; Cuberas, Gemma; Riera, E.; Solèr, M.; Moragas, M.; Lomeña, Francisco

doi:10.1097/mnm.0000000000000207

Cited by 6 publications

(3 citation statements)

References 28 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 43 studies, 13 were excluded: patients without biochemical relapse but with advanced disease or assessed for primary staging, i.e. inclusion criteria not fulfilled (3 studies [17][18][19]); intervention not in the inclusion criteria (1 study [20]); outcome of interest not reported (4 studies [21][22][23][24]); and no reference standard reported (5 studies [25][26][27][28][29]). Finally, 29 studies with 2,686 participants were included (Fig.…”

Section: Bibliographic Searchmentioning

confidence: 99%

PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data

Fanti

Minozzi²,

Castellucci

et al. 2015

Eur J Nucl Med Mol Imaging

205

107

View full text Add to dashboard Cite

There is a significant amount of (11)C-choline PET data published showing a high degree of consistency in inclusion criteria, acquisition protocols and scan interpretation criteria. Furthermore, the quality of the data derived limited to the same standard of reference was acceptable. Despite a high variability in the observed prevalence of any relapse, the diagnostic performance of (11)C-choline PET was in line with previous meta-analyses. Our data confirm the very good accuracy of (11)C-choline PET for detection of lymph node metastases and/or distant lesions in a single examination in patients with biochemical relapse.

show abstract

Section: Bibliographic Searchmentioning

confidence: 99%

PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data

Fanti

Minozzi²,

Castellucci

et al. 2015

Eur J Nucl Med Mol Imaging

205

107

View full text Add to dashboard Cite

show abstract

“…Dynamic acquisitions with choline labeled with 18 Fluorine are more appropriate than with 11 Carbon, because of the short half-life of 11 Carbon (20 min). However, a prospective study using 11 C-Choline in 56 patients performed with two successive whole-body acquisitions at about 3–5 and 20 min post-injection, demonstrated dual phase acquisition was useful in distinguishing benign from malignant lesions ( 23 ). Nevertheless, they used a different radiopharmaceutical and they did not acquire dynamic, therefore making comparisons to our study difficult.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer

et al. 2015

View full text Add to dashboard Cite

IntroductionDynamic image acquisition with 18F-Choline [fluorocholine (FCH)] PET/CT in prostate cancer is mostly used to overcome the bladder repletion, which could obstruct the loco-regional analysis. The aim of our study was to analyze early dynamic FCH acquisitions to define pelvic lymph node or prostate pathological status.Material and methodsRetrospective analysis was performed on 39 patients for initial staging (n = 18), or after initial treatment (n = 21). Patients underwent 10-min dynamic acquisitions centered on the pelvis, after injection of 3–4 MBq/kg of FCH. Whole-body images were acquired about 1 h after injection using a PET/CT GE Discovery LS (GE-LS) or Siemens Biograph mCT (mCT). Maximum and mean SUV according to time were measured on nodal and prostatic lesions. SUVmean was corrected for partial volume effect (PVEC) with suitable recovery coefficients. The status of each lesion was based on histological results or patient follow-up (>6 months). A Mann–Whitney test and ANOVA were used to compare mean and receiver operating characteristic (ROC) curve analysis.ResultsThe median PSA was 8.46 ng/mL and the median Gleason score was 3 + 4. Ninety-two lesions (43 lymph nodes and 49 prostate lesions) were analyzed, including 63 malignant lesions. In early dynamic acquisitions, the maximum and mean SUV were significantly higher, respectively, on mCT and GE-LS, in malignant versus benign lesions (p < 0.001, p < 0.001). Mean SUV without PVEC, allowed better discrimination of benign from malignant lesions, in comparison with maximum and mean SUV (with PVEC), for both early and late acquisitions. For patients acquired on mCT, area under the ROC curve showed a trend to better sensitivity and specificity for early acquisitions, compared with late acquisitions (SUVmax AUC 0.92 versus 0.85, respectively).ConclusionAssessment of lymph nodes and prostate pathological status with early dynamic imaging using PET/CT FCH allowed prostate cancer detection in situations where proof of malignancy is difficult to obtain.

show abstract

“…The pooled detection rate increased to 65% when PSA doubling time was 6 months or less and to 71 and 77% when PSA velocity was higher than 1 or higher than 2 ng/ml/year, respectively. During the last year, several studies have been published with choline PET/CT describing optimization of technique [33][34][35][36][37][38][39][40], and staging [41][42][43][44][45], restaging [46][47][48][49][50][51][52][53][54], radiation treatment planning [55 & ,56], and evaluation of treatment response [57]. Furthermore, two studies reported a prognostic value of choline PET/CT [58,59 & ].…”

Section: Cholinementioning

confidence: 99%

Advances in imaging modalities in prostate cancer

Bouchelouche

Türkbey²,

Choyke³

2015

Current Opinion in Oncology

View full text Add to dashboard Cite

Several advances in the imaging of PCa have been made during the past year. In particular, important clinical developments have been reported in multiparametric MRI, PET/computed tomography, and PET/MRI. The continuing development of imaging techniques in PCa has the potential to optimize treatment of PCa. However, the optimal imaging strategies for each of the major clinical scenarios in PCa have not yet been identified.

show abstract

Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence

Abstract: Dual-phase PET/CT with 11C-choline is technically feasible despite this tracer's short physical half-life and is useful for discriminating benign from malignant lesions. SUVvariation accurately discriminated between benign and malignant lesions.

Cited by 6 publications

References 28 publications

PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data

PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data

Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer

Advances in imaging modalities in prostate cancer

Contact Info

Product

Resources

About